{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:19:03Z","timestamp":1790651943270,"version":"4.1.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK","award":["HO-15-15772"],"award-info":[{"award-number":["HO-15-15772"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.vaccine.2018.08.080","type":"journal-article","created":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T10:02:03Z","timestamp":1537610523000},"page":"6810-6818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals"],"prefix":"10.1016","volume":"36","author":[{"given":"Juliana L.","family":"Meyers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D.","family":"Candrilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora A.","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songkai","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron J.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"S1","key":"10.1016\/j.vaccine.2018.08.080_b0005","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1386-6532(10)70002-0","article-title":"Advances in the understanding of the pathogenesis and epidemiology of herpes zoster","volume":"48","author":"Gershon","year":"2010","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2018.08.080_b0010","doi-asserted-by":"crossref","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2018.08.080_b0015","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.0000000000002808","article-title":"Quantification of risk factors for postherpetic neuralgia in herpes zoster patients","volume":"87","author":"Forbes","year":"2016","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.vaccine.2018.08.080_b0020","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.vaccine.2018.08.080_b0025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s15010-013-0550-8","article-title":"Incidence of herpes zoster in patients with altered immune function","volume":"42","author":"Chen","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2018.08.080_b0030","doi-asserted-by":"crossref","first-page":"g2911","DOI":"10.1136\/bmj.g2911","article-title":"Quantification of risk factors for herpes zoster: population based case-control study","volume":"348","author":"Forbes","year":"2014","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.vaccine.2018.08.080_b0035","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4065\/84.9.787","article-title":"Health care utilization and cost burden of herpes zoster in a community population","volume":"84","author":"Yawn","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.vaccine.2018.08.080_b0040","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1097\/01.tp.0000441826.70687.f6","article-title":"Herpes zoster-attributable resource utilization and cost burden in patients with solid organ transplant","volume":"97","author":"Palmer","year":"2014","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.vaccine.2018.08.080_b0045","doi-asserted-by":"crossref","first-page":"ofw067","DOI":"10.1093\/ofid\/ofw067","article-title":"Cost of herpes zoster in patients with selected immune-compromised conditions in the United States","volume":"3","author":"Li","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2018.08.080_b0050","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.4065\/mcp.2011.0305","article-title":"Herpes zoster and postherpetic neuralgia surveillance using structured electronic data","volume":"88","author":"Klompas","year":"2011","journal-title":"Mayo Clinic Proc"},{"issue":"3","key":"10.1016\/j.vaccine.2018.08.080_b0055","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/jmv.23830","article-title":"Immunity and the burden of herpes zoster","volume":"86","author":"Choi","year":"2014","journal-title":"J Med Virol."},{"key":"10.1016\/j.vaccine.2018.08.080_b0060","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/14760584.2017.1394843","article-title":"Varicella and herpes zoster vaccine development: lessons learned","volume":"16","author":"Warren-Gash","year":"2017","journal-title":"Exp Rev"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18312301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18312301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T20:55:10Z","timestamp":1544475310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18312301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":12,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0264410X18312301"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.08.080","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.08.080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}